Novel oral formulation of Insulin
The Invention Gagomers are novel particles (neither liposomes nor microspheres/nanospheres) composed of hyaluronan shell which is crossed linked to phospholipids and can be generated either as micro or nano particles. The research team at Tel Aviv University has demonstrated that: (1) Gagomers efficiently encapsulate fibrillar Insulin (2) gagomers are protecting the insulin in the GIT (3) Due to the hyaluronan shell Gagomers are targeting the Insulin to intestinal mucosa and show muco-adhesive properties in the intestine and (4) In vivo studies with diabetic (STZ-induced) mice, under conditions that mimic human eating habits, demonstrated an anti Glycemic effect reducing blood glucose levels from diabetic to normal. Potential Applications Oral delivery of mid to long-acting Insulin Advantages Targeting to intestinal mucosa with muco-adhesive properties Initial safety studies indicates a safe preparation Biocompatible and Biodegradable Stage Extensive in vitro studies on Gagomers production and fibrillar insulin encapsulation. In vivo proof of concept in STZ mice. Preliminary Safety data.Patent Pending application Tech Transfer Officer Dr. Nissim Chen Office: +972-3-6406121 Fax: +972-3-6406675 The Invention Gagomers are novel particles (neither liposomes nor microspheres/nanospheres) composed of hyaluronan shell which is crossed linked to phospholipids and can be generated either as micro or nano particles. The research team at Tel Aviv University has demonstrated that: (1) Gagomers efficiently encapsulate fibrillar Insulin (2) gagomers are protecting the insulin in the GIT (3) Due to the hyaluronan shell Gagomers are targeting the Insulin to intestinal mucosa and show muco-adhesive properties in the intestine and (4) In vivo studies with diabetic (STZ-induced) mice, under conditions that mimic human eating habits, demonstrated an anti Glycemic effect reducing blood glucose levels from diabetic to normal. Potential Applications Oral delivery of mid to long-acting Insulin Advantages Targeting to intestinal mucosa with muco-adhesive properties Initial safety studies indicates a safe preparation Biocompatible and Biodegradable Stage Extensive in vitro studies on Gagomers production and fibrillar insulin encapsulation. In vivo proof of concept in STZ mice. Preliminary Safety data.
Inventor(s): Rimona Margalit
Type of Offer: Licensing
« More Biotech Patents